Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion-Reference-Cited by-同舟云学术

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

Published:2016-04-03 Issue:3 Volume:2 Page:200-205
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:Eur Heart J Cardiovasc Pharmacother

Author:

Zannad Faiez,Stough Wendy Gattis,Lipicky Raymond J.,Tamargo Juan,Bakris George L.,Borer Jeffrey S.,Alonso García Maria de los Angeles,Hadjadj Samy,Koenig Wolfgang,Kupfer Stuart,McCullough Peter A.,Mosenzon Ofri,Pocock Stuart,Scheen André J.,Sourij Harald,Van der Schueren Bart,Stahre Christina,White William B.,Calvo Gonzalo

Funder

Association de Recherche et d'Information en Cardiologie

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/article-pdf/2/3/200/6721979/pvw007.pdf

Reference47 articles.

1. Food and Drug Administration. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM071627.pdf (last updated: 2008; accessed: 24 July 2015) .

2. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

3. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

4. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

5. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials;Clinical Cardiology;2024-07

2. Cardiovascular outcome with SGLT2i and GLP1RA;European Journal of Internal Medicine;2024-06

3. A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications;Heliyon;2024-03

4. Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients;Heart and Vessels;2023-07-31

5. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study;Cardiovascular Diabetology;2023-06-28